The QualityStocks Daily Thursday, March 4th, 2021

Today's Top 3 Investment Newsletters

QualityStocks(FPRX) +78.74%

INO Market Report(SLGG) +69.29%

MicroCapDaily(SPRV) +47.68%

The QualityStocks Daily Stock List

Avinger Inc. (NASDAQ: AVGR) (FRA: VG2B)

MarketBeat, StockMarketWatch, StreetInsider, Marketbeat.com, Barchart, BUYINS.NET, TraderPower, The Online Investor, Stock Beast, Zacks, Profitable Trader Authority, Faisam Trader, OTCtipReporter, Penny Pick Finders, Penny Stock Prodigy, AwesomeStocks, PennyStockScholar, Promotion Stock Secrets, QualityStocks, Street Insider, TradersPro and PennyStockProphet reported earlier on Avinger Inc. (AVGR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Avinger Inc. (NASDAQ: AVGR) (FRA: VG2B) is a medical device firm that is focused on designing, manufacturing and commercializing catheter-based and image guided systems which are used by physicians to treat peripheral artery disease patients.

Avinger Inc. is based in Redwood City in California and was founded on March 8, 2007 by Himanshu N. Patel and John B. Simpson. Avinger Inc. is part of the medical equipment and supplies manufacturing industry and serves consumers in United States and also internationally. However, the majority of the firm’s revenue is generated from sales in the U.S.

Avinger Inc. markets and sells its products to interventional radiologists and cardiologists as well as vascular surgeons. The firm is dedicated to changing the way vascular ailments are treated using its lumivascular platform. Avinger Inc.’s products include the lumivascular platform, which has combined interventional catheters and optical

coherence tomography visualization to offer intravascular imaging during peripheral artery disease treatment. The firm’s lumivascular products are made up of an image-guided device used by physicians to remove arterial plaque in peripheral artery disease patients. These products include Pantheris, Ocelot catheters; Ocelot PIXL, Ocelot MVRX and Ocelot, which have been developed to penetrate blockages in arteries and Lightbox imaging consoles. Other products by the firm include Kittycat 2, Juicebox and Wildcat.

Avinger Inc. is the first company to manufacture an image-guided catheter-based system and was recently awarded an optical pressure sensor assembly patent. Majority of physicians prefer minimally invasive procedures, as they expose the patient to less risk and healing is faster. Avinger Inc. will continue to grow as it continues producing minimally invasive technologies, which will also be good for the company’s stocks.

Avinger Inc. (AVGR), closed Thursday's trading session at $1.39, off by 14.7239%, on 7,966,010 volume with 15,890 trades. The average volume for the last 3 months is 26,725,523 and the stock's 52-week low/high is $0.213899999/$2.67000007.

Fortress Biotech Inc. (NASDAQ: FBIO) (FRA: CNB)

StockMarketWatch, MarketBeat, TradersPro, Marketbeat.com, TraderPower, BUYINS.NET, QualityStocks, StreetInsider, Tiny Gems, The Street, Penny Stock Prodigy, Money Morning, Barchart and AllPennyStocks reported earlier on Fortress Biotech Inc. (FBIO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Fortress Biotech Inc. (NASDAQ: FBIO) (FRA: CNB) is a biopharmaceutical firm that is engaged in the acquisition, development and commercialization of biotechnology and pharmaceutical products.

Fortress Biotech Inc. is based in New York and was founded on June 28, 2006. The firm changed its name to Fortress Biotech Inc. from Coronado Biosciences Inc. in April 2015. Fortress Biotech Inc. has collaboration agreements with various pharmaceutical companies, research institutes and universities.

The company provides management and funding services to subsidiaries under it and operates through the following segments; Pharmaceutical and Biotechnology Product Development and Dermatology Product Sales. The firm sells dermatology products like Ximino, which is used to treat inflammatory lesions caused by serious acne vulgaris; Ceracade, which is used to manage dry skin; Luxamend, which is used to manage and dress wounds; Exelderm cream, which is used to manage symptoms of jock itch and ringworm; and Targadox, which is used for acne.

Fortress Biotech’s product portfolio includes a chimeric antigen receptor engineered T-cell (CAR T) program for light chain amyloidosis and multiple myeloma known as CS1, a CAR T for non-Hodgkin lymphoma dubbed MB-106, a CAR T program for acute myeloid leukemia dubbed MB-102 and gene therapy for severe combined immunodeficiency christened MB-107. The firm is also developing MP-105, MB-108, MB-103 and MB-101, which are used for pancreatic and prostate cancers, glioblastoma multiform (GBM), GBM, brain and breast cancer metastases and GBM, respectively.

Fortress Biotech recently entered into an agreement with Sentynl Therapeutics and Cyprium Therapeutics to purchase Cyprium’s product candidate CUTX-101, which has been indicated for the treatment of Menkes disease. This transaction with Sentynl will not only help develop more effective treatments that can be made available to patients but also allow the firm to maximize shareholder value through the partnership.

Fortress Biotech Inc. (FBIO), closed Thursday's trading session at $4.13, off by 10.2174%, on 2,210,167 volume with 13,440 trades. The average volume for the last 3 months is 979,759 and the stock's 52-week low/high is $1.03999996/$5.07999992.

Kaixin Auto Holdings (NASDAQ: KXIN) (FRA: K64)

StockMarketWatch, MarketClub Analysis, TradersPro, The Street, QualityStocks, MarketBeat and InvestorPlace reported earlier on Kaixin Auto Holdings (KXIN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Kaixin Auto Holdings (NASDAQ: KXIN) (FRA: K64) is a holding company which also operates as an investment firm. The firm’s subsidiaries operate or own used car dealerships and the company is among the main dealership networks in the premium used car segment in China.

Formerly known as CM Seven Star Acquisition Corp., Kaixin Auto Holdings is based in Beijing in the People’s Republic of China and was founded in 2015. The firm is a Renren Inc. subsidiary and focuses on car brands like Porsche, Land Rover, Mercedes-Benz, BMW and Audi.

Kaixin Auto Holdings’ operating segment is inclusive of automobile sales. Geographically speaking, the firm derives its revenue from China. However, the majority of Kaixin Auto’s revenue is generated from the automobile sales segment; the sale of used cars and fees received for the role the firm plays as a channel partner for 3rd party auto financing.

Kaixin Auto Holdings provides value-added services such as after sales services, extended warranties and insurance to its consumers. Additionally, it offers financing channels to its consumers through its collaborations with financial institutions.

Kaixin Auto Holdings recently announce its purchase agreement with Haitaoche Ltd shareholders. Haitaoche is an online retail platform that imports automobiles and with the used car market in China continuing to grow rapidly combined with this partnership, the firm’s sales are bound to increase, which will prompt further growth and good returns.

Kaixin Auto Holdings (KXIN), closed Thursday's trading session at $2.78, off by 20.7977%, on 4,803,139 volume with 14,480 trades. The average volume for the last 3 months is 3,575,459 and the stock's 52-week low/high is $0.400099992/$13.3999996.

PolarityTE Inc. (NASDAQ: PTE) (FRA: NJTC)

StockMarketWatch, MarketBeat, BUYINS.NET, Zacks, StreetInsider, Schaeffer's, Trading Concepts, Trades Of The Day and QualityStocks reported previously on PolarityTE Inc. (PTE), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

PolarityTE Inc. (NASDAQ: PTE) (FRA: NJTC) is a regenerative biomaterials and biotechnology firm which is engaged in the development and commercialization of various regenerative biomaterials and tissue products for the fields of material sciences, biomedical engineering and medicine.

PolarityTE Inc., which changed its name from Majesco Entertainment, is based in Salt Lake City, Utah and was founded on May 8, 1998. The firm serves consumers in the United States.

PolarityTE Inc. operates in 2 segments, i.e. Contract Services and Regenerative Medicine. The firm offers contract research services and is currently pursuing regulatory approval for technology which will use an individual’s tissue substrates to regenerate nerves, blood vessels, fat, cartilage, muscle, bone and skin.

PolarityTE Inc.’s portfolio includes a biologically active allogenic dressing which is used in aesthetics and wound care to speed up the skin’s healing. It is called PTE 11000. There is also a tissue product developed to repair, reconstruct, replace and supplement the skin of patients who need treatment for burns, chronic or acute wounds defects known as SkinTE. The firm also develops an autologous construct that assists in bowel tissue regeneration, BowelTE; a product that addresses causes of liver failure, LiverTE; a product for patients with carpal tunnel syndrome, migraines, craniofacial injuries, chronic compression because of joint replacements or neuromas called NeuralTE; a vascular regeneration product, AngioTE; a cartilage regeneration product, CartTE and a homologous bone regeneration product called OsteoTE.

PolarityTE Inc. uses a biologically sound and natural platform that can readily be adapted to a wide range of tissue systems and organs. This affords an advantage which will allow it to revolutionize the future and field of translational regenerative medicine.

PolarityTE Inc. (PTE), closed Thursday's trading session at $1.28, off by 7.9137%, on 6,596,194 volume with 10,970 trades. The average volume for the last 3 months is 8,896,127 and the stock's 52-week low/high is $0.552999973/$2.38000011.

Quanta, Inc. (QNTA)

QualityStocks, Small Cap Firm, StockHideout, OTCBB Journal and Broad Street reported beforehand on Quanta, Inc. (QNTA), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter. 

Quanta, Inc. is an applied science company focused on enhancing energy levels in plant matter, including hemp and cannabis, to boost performance within the human body. Its proprietary technology uses quantum mechanics to increase bioactivity of targeted molecules to enhance the desired effects. Quanta specializes in potentiating rare, naturally occurring elements to create impactful and sustainable healing solutions that are as powerful and predictable as pharmaceutical drugs. Established in 2016, Quanta is headquartered in Los Angeles, California. The Company lists on the OTC Markets.

Quanta offers its technology as a platform to product makers by way of distribution channels and consumer products. It serves brands in cannabis, anti-aging, health and wellness, stress management, pain management, fitness and brain performance enhancement.

Quanta’s CBD (cannabidiol) pain relief rub is an all-natural CBD topical that consists of 13 natural elements. These include turmeric, arnica and polarized CBD. The design is to provide relief from pain, inflammation, and also stiffness in muscles and joints.

Quanta has partnered with Kapno to sell the Company's CBD Muscle Rub and CBD Vape. Kapno distributes brands online via its existing worldwide network. Kapno has 2.4 billion followers across all social platforms.

Quanta CBD Muscle Rub is a premium organic and the balm works to increase circulation, ease aches and pains, and provide maximum relief, comfort, and overall well-being. Quanta has since launched three additional products to assist in their mission with the aforementioned CBD Vape, Muscle Rub PLUS, and Sensitive Skin version of their flagship Muscle Rub.

Quanta products have gained a loyal following month over month, with the online repurchase rate, which grew to 26.8 percent according toa recent quarterly report, along with seeing their B2B (Business to Business) customers, grow at a rate of 119.2 percent compared to the prior quarter. The Company also announced that sales for its patented polarized products grew at a 37.8 percent rate during the same quarter over quarter period.

Quanta, Inc. (QNTA), closed Thursday's trading session at $0.08, up 10.6501%, on 123,185 volume with 17 trades. The average volume for the last 3 months is 195,572 and the stock's 52-week low/high is $0.014999999/$0.25.

Fourth Wave Energy, Inc. (FWAV)

QualityStocks, StockRockandRoll, PennyStockLocks and Penny Stock 101 reported earlier on Fourth Wave Energy, Inc. (FWAV), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Fourth Wave Energy, Inc. is a climate solutions enterprise. The Company focuses on eliminating greenhouse gas emissions from the build environment. Its Management Team has greater than 125 years of experience in alternative energy, financial markets, as well as construction. The Team’s emphasis is on developing scalable solutions that lessen reliance on fossil fuels and minimize the release of greenhouse gasses.

Fourth Wave Energy was acquired by Pierre Corp. in an all-stock transaction in March of this year. Fourth Wave Energy is based in Denver, Colorado. In addition, it has regional offices in San Jose, California, and Dallas, Texas. The Company lists on the OTC Markets Group’s OTCQB.

Fourth Wave channels the power of the earth and sun to power residences while substantially decreasing the need for fossil fuels and reliance on utility power. The Company delivers integrated energy-efficient design, high-performance components, as well as meticulous construction standards. It delivers net zero energy results in retrofits and new construction. Fourth Wave is rolling out new and retrofit geo-solar powered homes and communities to address market potential.

The Company is centering on the growing net-zero market via the use of its new GeoSolar Plus™ (GSP) total home energy makeover system. Fourth Wave Energy’s plan is to take advantage of its expertise in the use of energy efficient building techniques, including geothermal applications and on-site solar power generation, to attain commercial scalability in providing near-zero carbon homes.

Recently, Fourth Wave Energy announced that it is currently raising capital for operations and for the closing of the recently announced potential acquisition of Desol Power Tiles. If the acquisition is completed, Fourth Wave Energy’s plan is to manufacture, market, and also distribute across North America solar tile roofs designed by DeSol Power Tiles. Fourth Wave has targeted sales and marketing teams with access to builders, roofers, solar installers, and developers throughout the United States to act as its sales agents. The DeSol Tile was developed and patented in the USA by a Belgium based solar engineer in response to the increasing need for an ascetically pleasing solar roofing option.

Fourth Wave Energy, Inc. (FWAV), closed Thursday's trading session at $0.46, up 21.372%, on 238,845 volume with 62 trades. The average volume for the last 3 months is 72,828 and the stock's 52-week low/high is $0.100100003/$0.829999983.

BrewBilt Manufacturing, Inc. (BBRW)

We reported  previously on BrewBilt Manufacturing, Inc. (BBRW), and today we report on the Company, here at the QualityStocks Daily Newsletter.

BrewBilt Manufacturing, Inc. is one of the only California companies that custom designs, hand crafts, and integrates processing, fermentation, and distillation processing systems for the craft beer, cannabis, and hemp industries. The Company uses "Best in Class" U.S. made components integrated with stainless steel processing vessels using only American made steel. BrewBilt Manufacturing’s dedication is to helping build the craft beer community one brewery at a time. Founded in 2014, BrewBilt Manufacturing is headquartered in Grass Valley, California. The Company lists on the OTC Markets.

All BrewBilt Manufacturing products are designed and fabricated as "food grade" quality. This enables the Company to manufacture vessels for food & beverage processing. BrewBilt has been making systems that are pharmaceutical grade for clients involved in distillation for the cannabis and hemp industries over the past 36 months, thus making the revenue potential considerably greater.

The Company works with its clients every step of the way. This is from concept to opening. BrewBilt helps its clients keep on track. This is from working with their bankers on financing solutions, their architect and contractor on equipment layout, to scheduling, logistics, and continuing project management.

BrewBilt provides a six-year material and workmanship warranty on everything it builds. The BrewBilt team includes brewers, design engineers, craftsmen, and owners with greater than 50 years of business experience.

Recently, BrewBilt Manufacturing announced that it will officially compete as a part of the $500B beer brewing industry in 2021. With its new strategic partnership, it has agreed to immediately fulfill craft beer orders in China, Finland, as well as San Francisco.

BrewBilt Manufacturing, Inc. (BBRW), closed Thursday's trading session at $0.007, up 34.6154%, on 501,600,123 volume with 4,397 trades. The average volume for the last 3 months is 212,181,967 and the stock's 52-week low/high is $0.00127/$0.089900001.

Five Prime Therapeutics, Inc. (FPRX)

TopStockAnalysts, StreetAuthority Daily, MarketBeat, MissionIR, QualityStocks, Daily Trade Alert, InvestorPlace, StreetInsider, ProfitableTrading, Trades Of The Day, MarketClub Analysis, Top Pros' Top Picks, Cabot Wealth, TradersPro, Zacks, INO.com Market Report, BUYINS.NET, The Street, Investing Futures, Barchart, StockMarketWatch, The Trading Report, Tiny Gems, Weekly Wizards and Short Term Wealth reported previously on Five Prime Therapeutics, Inc. (FPRX), and today we report on the Company, here at the QualityStocks Daily Newsletter. 

Five Prime Therapeutics, Inc. is developing novel immuno-oncology protein therapeutics. The Company is working to develop immune modulators and precision therapies for solid tumor cancers. Its product candidates have innovative mechanisms of action and address patient populations in need of better therapies. A clinical-stage biotechnology company, Five Prime Therapeutics is based in South San Francisco, California. The Company’s shares trade on the NasdaqGS.

Five Prime concentrates on researching and developing immuno-oncology and targeted cancer therapies paired with companion diagnostics to identify patients who are most likely to benefit from treatment with its product candidates. The Company has entered into strategic collaborations with leading global pharmaceutical companies. It has promising product candidates in clinical and preclinical development.

Five Prime programs include Bemarituzumab - FGFR2B Antibody - FIGHT trial (with chemo) in 1L gastric/GEJ cancer; and FPA150 B7-H4 Antibody - Breast, ovarian and endometrial cancers. Furthermore, programs include FPT155 - CD80-FC Fusion - Multiple tumor settings; and I-O Antibodies - Multiple tumor settings.

Bemarituzumab (anti-FGFR2b) is a first-in-class isoform-selective antibody with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) in development as a targeted immunotherapy for tumors that overexpress FGFR2b. Bemarituzumab is undergoing evaluation in combination with mFOLFOX6 in the Phase 3 FIGHT (FGFR2b Inhibition in Gastric and Gastroesophageal Junction Cancer Treatment) trial.

The FIGHT trial is being converted to a Phase 2 randomized, double-blind trial, based on the approximately 150 patients enrolled. The expectation is that the Phase 2 FIGHT study will have a sufficient number of PFS and OS events to generate clinically meaningful and actionable data by early 2021. Converting to a Phase 2 trial is the fastest path to generating informative data concerning bemarituzumab: the first agent to target FGFR2b overexpressing gastric and gastroesophageal junction cancer (GEJ).

Five Prime Therapeutics, Inc. (FPRX), closed Thursday's trading session at $38.00, up 78.7394%, on 35,380,129 volume with 120,290 trades. The average volume for the last 3 months is 937,123 and the stock's 52-week low/high is $1.75/$38.1800003.

Allied Esports Entertainment, Inc. (AESE)

StockMarketWatch, QualityStocks, StockOnion, Profitable Trader Authority, PennyStockScholar, PennyStockProphet, Penny Pick Finders, OTCtipReporter, MarketBeat, InvestorsUnderground, Hototc and Buzz Stocks reported previously on Allied Esports Entertainment, Inc. (AESE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Allied Esports Entertainment, Inc. is a worldwide esports entertainment company listed on the NasdaqGS. It provides unique infrastructure, transformative live experiences, multiplatform content and interactive services to audiences globally via its strategic fusion of two strong entertainment brands: Allied Esports International, Inc. (Allied Esports) and the World Poker Tour (WPT). Incorporated in 2017, Allied Esports Entertainment is based in Irvine, California.

Allied Esports is an award-winning esports enterprise consisting of an international network of dedicated esports properties and content production facilities. Its mission is to connect players, streamers and fans globally through integrated arenas, including its flagship venue, HyperX Esports Arena Las Vegas, its fleet of mobile esports trucks, the HyperX Esports Trucks, and affiliate members of the Allied Esports Property Network that serve as competition battlegrounds and everyday content generation hubs.

World Poker Tour is the premier name in globally televised gaming and entertainment. It has brand presence in land-based tournaments, television, online, as well as mobile. In 2002, WPT sparked the worldwide poker boom with the creation of its iconic television show, now in its 18th season, based on a series of high-stakes poker tournaments. ClubWPT.com is an innovative online membership platform that offers inside access to the WPT.

Recently, the WPT® and its partner, partypoker, announced the first WPT Online Series that will take place exclusively on the partypoker platform. The $3,200 buy-in, $5 million guaranteed WPT Online Championship will highlight the schedule.

The entire partypoker series includes $30 million in guarantees and $7 million for the WPT events on the schedule. partypoker.com is one of the oldest, most recognized and trusted online poker brands. Launched in August 2001, partypoker.com is one of the pioneers of the online poker industry.

Allied Esports Entertainment, Inc. (AESE), closed Thursday's trading session at $3.27, up 30.80%, on 95,513,884 volume with 280,420 trades. The average volume for the last 3 months is 3,491,559 and the stock's 52-week low/high is $0.400000005/$5.94000005.

Simlatus Corporation (SIML)

QualityStocks, SmallCapVoice, Small Cap Stock Alert, PHUB News, DSR News, Wealth Insider Alert, Timothy Sykes, MarketBeat and Epic Stock Picks reported previously on Simlatus Corporation (SIML), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter. 

Simlatus Corporation focuses on opportunities in the cannabis space. A holding company, it owns and operates several subsidiaries with numerous revenue streams in the CBD (cannabidiol) industry. Proscere Bioscience, Inc. is the Company’s division centered on the CBD industry. Simlatus is based in Grass Valley, California.

The Company’s diversity includes other subsidiaries, including Satel Group. Satel is a premier high-rise DirecTV provider for the financial, commercial and residential metropolitan San Francisco Bay area. In addition, the Company’s subsidiaries include Simlatus, a manufacturer of audio/video products, which presently sells to DirecTV, CBS, Fox News and Warner Bros.

Simlatus manufactures and markets commercial High-Definition (HD) and Analog audio/video systems for the worldwide broadcast studio industry. The Company continues to lead the commercial industry with high-end equipment. Its “SyncPal™ and Simlatus-IBS™ are for revolutionizing studio management and audio/video control using smartphones or smart glasses.

Regarding the Digital Media and Augmented/Virtual Reality device industry, Simlatus’ SocialCast AR and Augmented/Virtual Reality Content Server products will permit Simlatus to expand into high-growth digital television and over-the-top (OTT) markets. The Company is developing technologies in Virtual Reality, Augmented Reality, Audio/Video Codecs, Audio Content Recognition, and OTT API Integration.

In October 2019, Simlatus announced that certifications and manufacturing processes were initiated to begin the manufacturing and delivery pursuant to the purchase orders for the CBD Extraction Systems. Its subsidiary, Proscere Bioscience, received purchase orders for the delivery of 14 CBD Extraction Systems in value of $24M.

Recently, Simlatus announced that Proscere Bioscience secured the rights to manufacture a CBD - Hybrid Extraction System with integrated cold-water and alcohol extraction technologies. Proscere will manufacture the world’s first Hybrid Cold-Water/Alcohol Extraction System for CBD.

Mr. Richard Hylen, Chief Executive Officer of Simlatus, stated, “Having secured the technological rights to build and bring to market the world’s first Hybrid Extraction System for CBD is certainly a game changer for the Company. This Hybrid System will initially process biomass through cold-water extraction, then alcohol extraction via an integrated system that results in very high quality pharmaceutical grade CBD and commercial grade CBD from the same biomass.”

Simlatus Corporation (SIML), closed Thursday's trading session at $0.00259, up 52.3529%, on 2,959,509,389 volume with 6,876 trades. The average volume for the last 3 months is 386,316,268 and the stock's 52-week low/high is $0.000000999/$0.499799996.

Cannabis Suisse Corp. (CSUI)

QualityStocks, OTCtipReporter, Profitable Trader Authority, PennyStockScholar, PennyStockProphet, StockOnion, Penny Pick Finders, Buzz Stocks, Penny Picks, HotOTC, Damn Good Penny Picks, BeatPennyStocks and AwesomeStocks reported beforehand on Cannabis Suisse Corp. (CSUI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Cannabis Suisse Corp. operates as a licensed cannabis cultivation and distribution enterprise for recreational tobacco products and medical CBD (cannabidiol) oils in Switzerland. It is a research & development (R&D) organization licensed under Swiss Cannabis and tobacco regulations to cultivate and sell cannabis. Its main activities in producing cannabis are based in Zurich, Switzerland. The Company grows high quality, organic cannabis with sustainable, all-natural principles. In August of 2018, Forbes magazine listed Switzerland as the third most overlooked marijuana market worldwide.

The Company was previously known as Geant Corp. It changed its name to Cannabis Suisse Corp. in February of this year. Established in 2016, Cannabis Suisse has its head office in Dietikon, Switzerland.

The Company operates in Europe and pursues new and developing cannabis markets where possible via its own network of wholesale distributors, its e-commerce and mobile applications, brick and mortar retail stores, and grocery store retailers.

Cannabis Suisse provides high CBD tobacco substitutes made from the well-known strains with low THC (tetrahydrocannabinol) and high CBD. The Company extracts CO2 for its own production and for manufacturers/farmers in Switzerland. It clones its own mother plants. As a result, it ensures the quality and taste will be consistent each time customers use its products.

Cannabis Suisse produces chocolate beans, e-cigarette oil, and also tea products with high CBD percentage. Its cannabis is stored in a cool, dark location for optimal results. The ideal storage temperature for the finished dried cannabis product is 2 °C to 6 °C with a shelf-life of 12 months.

The Company has entered into a partnership with Royal Danish Cigars Ltd. This partnership is to develop a luxury product line of cannabis and tobacco blended cigars, marketed under the label SwissCigars™. SwissCigars™ will produce 1 percent THC versions for local consumption and 0.2 percent THC cigars legal for export. These cannabis cigars will be hand rolled in Switzerland by Cuban master rollers. They will subsequently be decorated with 24 KT Swiss Gold and Swarovski.

Cannabis Suisse has strategic investments and Swiss partnerships. With these the Company provides a broad array of first-rate quality cannabis and hemp products, develops unique technologies, promotes cannabis consumer health and wellness, and delivers a premier customer experience with its brand CannaMec™.

This week, Cannabis Suisse announced the launching of a new product in its retail brand Alpine Cannabis. Alpine Cannabis CBD Pure Base is an e-liquid for electronic cigarettes. It’s a boost of CBD to any e-liquids. It comes with different levels of CBD strengths.

Alpine Cannabis CBD Pure Base provides Certified CBD concentration in a 10 mL bottle. It is guaranteed without THC and is nicotine free. It contains no alcohol, and no animal extracts and has USP/Food Grade ingredients. The products is tamper-proof and child-proof and diacetyl free and quality controlled.

Cannabis Suisse Corp. (CSUI), closed Thursday's trading session at $0.0771, up 10.1429%, on 199,858 volume with 32 trades. The average volume for the last 3 months is 405,517 and the stock's 52-week low/high is $0.041000001/$1.14999997.

Bespoke Extracts, Inc. (BSPK)

We reported beforehand on Bespoke Extracts, Inc. (BSPK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bespoke Extracts, Inc. is a producer of high quality, flavorful, hemp-derived cannabidiol (CBD) extract products. The Company established in early 2017 to introduce a proprietary line of premium quality, all-natural CBD products in the form of tinctures and capsules for the nutraceutical and veterinary markets. Bespoke Extracts is headquartered in Sunny Isles Beach, Florida. The Company’s shares trade on the OTC Markets Group’s OTCQB.

The Company’s products are marketed as dietary supplements and distributed through the Company’s direct-to-consumers e-commerce store. Bespoke’s products are produced using pure, all natural, zero-THC phytocannabinoid-rich (PCR) hemp-derived CBD. CBD is non-psychoactive. CBD (cannabidiol) is one of over 85 cannabinoids found in cannabis. CBD is present in more significant quantities in hemp than it is marijuana.

Bespoke Extracts’ mission is to become one of the world’s most trusted sources for premium quality, all-natural, USA-grown, hemp-derived cannabidiol (CBD) products for the nutraceutical and veterinary markets. The Company strives to use only vegan, Fair Trade Certified, and organic ingredients with fast acting benefits for anyone looking for an alternative remedy. Bespoke’s farmers have been innovators in hemp agriculture, farming practices, agrotech, as well as production for generations. Bespoke’s hemp is stable, high in CBD, low in THC, and resistant to pathogens and pests.

The Company’s products include Sport Lemon Lime Tincture – THC Free 1500MG; CBD Manuka Honey Tincture; and CBD Bacon Flavored Pet Tincture. Moreover, products include CBD Softgel Capsules; CBD Pain Relief Cream; and CBD Isolate Powder.

Bespoke Extracts announced this past November that its Board of Directors appointed Niquana (Nikki) Noel as President and Chief Executive Officer (CEO), effective immediately. Serving Bespoke as its Operations Manager, Noel assumed day-to-day leadership of the Company and joined its Board of Directors. Noel has spent close to two decades working with privately-held and publicly-traded micro and small cap companies.

Bespoke Extracts, Inc. (BSPK), closed Thursday's trading session at $0.0457, up 38.4848%, on 457,927 volume with 47 trades. The average volume for the last 3 months is 475,774 and the stock's 52-week low/high is $0.007499999/$0.101649999.

Royale Energy,  Inc. (ROYL)

QualityStocks, MarketBeat, All about trends, Lebed.biz, Greenbackers, OTCPicks, PennyToBuck, PennyOmega, StockHotTips, SmarTrend Newsletters, CRWEWallStreet, CRWEPicks, CRWEFinance, BestOtc, Wall Street Resources, DrStockPick, SmallCapVoice, Daily Markets, OTC Picks, FeedBlitz, SmallCapInvestor.com, Turn Key Oil, TradingMarkets, StreetInsider, MicrocapVoice, The Street, Street Insider, Stock Analyzer, Dynamic Wealth Report, Oakshire Financial, PennyTrader Publisher, Hit and Run Candle Sticks, Investing Futures, Jason Bond, PennyStockDD, Penny Stock Rumble, Marketbeat.com, Microcapmillionaires, WealthMakers and FNNO Newsletters are reporting on Royale Energy,  Inc. (ROYL), here at the QualityStocks Daily Newsletter.

Royale Energy, Inc. concentrates on the acquisition, development, and marketing of natural gas and oil. It owns and operates wells in the Sacramento and San Joaquin basins in California and has royalty interests in Alaska.  The Company engages in the production and sale of natural gas;  the acquisition of oil and gas lease interests and proved reserves;  the drilling of exploratory and development wells; and the sale of fractional working interests in wells to undergo drilling. Royale Energy has its corporate office in El Cajon, California. 

Royale Energy has properties encompassing more than 20,000 acres in California and nine 3D seismic surveys in the Sacramento Basin. Currently, the Company operates greater than 60 natural gas wells. It owns interests in 12 natural gas fields in California.

Royale Energy’s North Arbuckle is in Colusa County in the Sacramento Basin. At present, this is the most active area for the Company. It has 10 producing natural gas wells that have produced over 5 billion cubic ft.

Royale has acquired greater than 96,000 acres on the Alaskan North Slope. The acreage spans over 88 miles east and west of the Trans-Alaska pipeline route.

The Company has its Lonestar Field. It includes in excess of 1,000 acres. The Lonestar Field has produced more than five billion cubic ft. of gas from five separate Forbes sandstone reservoirs. The Lonestar Field includes the Goddard 7-1 Well; the Goddard #2 and Goddard #3 (offset wells to the Goddard 7-1); and the Magnum Well.

Additionally,  Royale’s Victor Ranch Field is in Tehama County, in the Northern Sacramento Basin. This field has been producing natural gas for the Company since it drilled its first well there in 1993.

Royale Energy has an agreement with a major independent exploration and development company to expand its joint development agreement in the Sacramento Basin of Northern California. The expanded arrangement covers about 1,900 acres in the Rio Vista Gas Field. Royale will target the Capay and Martinez sands.

Royale Energy and Matrix Oil Management Corporation jointly announced earlier in 2018 the closing and completion of the merger between Royale and Matrix. The merger transaction was approved by the Matrix and Royale Energy shareholders on November 16, 2017. It closed after the companies received the consent of Matrix’s lender, Arena Limited SPV, LLC.

Royale Energy and CIC Partners have created a new Joint Venture (JV) named RMX Resources. This JV will fund, drill and produce oil at the prolific Sansinena Oil Field. CIC contributed an aggregate of $25,000,000 in cash in exchange for an 80 percent equity interest. Royale Energy received a 20 percent equity interest plus working capital in exchange for contribution of Sansinena and surrounding area assets. CIC is a Dallas-based private equity organization.

Royale Energy previously announced the appointment of Board Director Mr. Rod Eson as Chief Executive Officer (CEO) effective (immediately). Before accepting the CEO responsibilities at Royale Energy, Mr. Eson served as the CEO of Foothill Energy LLC, a California-focused company he founded in 2004.

Royale Energy,  Inc. (ROYL), closed Thursday's trading session at $0.156, up 28.9256%, on 19,786 volume with 21 trades. The average volume for the last 3 months is 70,649 and the stock's 52-week low/high is $0.0401/$0.229499995.

Vision Marine Technologies Inc. (NASDAQ: VMAR)

QualityStocks and StreetInsider reported previously on Vision Marine Technologies Inc. (VMAR), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Vision Marine Technologies Inc. (NASDAQ: VMAR) traded at a new 52-week low today of $9.42. So far today approximately 276,000 shares have been exchanged, as compared to an average 30-day volume of 233,000 shares.

Vision Marine Technologies Inc is engaged in designing and manufacturing electric outboard powertrain systems and our related technology. The company manufactures hand-crafted, highly durable, low maintenance, environmentally-friendly electric recreational powerboats. Its manufacturing models of electric powerboats include Phoenix 290, Bruce 22, Volt 180, Fantail 217, and Quietude 156.

In the past 52 weeks, shares of Vision Marine Technologies Inc. have traded between the current low of $9.42 and a high of $17.90 and is now at $10.00.

Vision Marine Technologies Inc. (NASDAQ:VMAR) has potential upside of 15.7% based on a current price of $10.00 and analysts' consensus price target of $11.57.

Vision Marine Technologies Inc. (VMAR), closed Thursday's trading session at $9.23, off by 9.7752%, on 259,253 volume with 2,089 trades. The average volume for the last 3 months is 409,876 and the stock's 52-week low/high is $9.00/$17.8999996.

The QualityStocks Company Corner

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) was featured today in a publication from MiningNewsWire, examining how, during the last quarter of 2020, the mining and metals industry in North America registered a 6.98% decline in cross-border deal activity. This is according to the most recent data from analysis conducted by GlobalData, which compared numbers from 2020’s last quarter to the average of the last four quarters. While the average of the last four quarters had 43 cross-border deals, 2020’s final quarter announced 40 cross-border deals in the region, which were valued at $2.4 billion.

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR),based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon‐free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

Energy Fuels Inc. (UUUU), closed Thursday's trading session at $5.37, off by 8.3618%, on 6,647,372 volume with 29,150 trades. The average volume for the last 3 months is 5,392,825 and the stock's 52-week low/high is $0.779999971/$6.9499998.

Recent News

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

Investor interest sent microcap stocks sky-high in 2020, a trend that is continuing well into 2021 with returns on some microcap ETFs surging at several times the rate of comparable large-cap ETFs (https://ibn.fm/Bu86D). As the tide of investor interest continues to flow into microcaps, public companies are leveraging the power of data through Sequire, SRAX's (NASDAQ: SRAX) investor analytics SaaS platform that unlocks data and insights critical to targeted marketing campaigns in order to engage current traders and attract new investors.

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Thursday's trading session at $4.03, off by 7.3563%, on 752,481 volume with 3,718 trades. The average volume for the last 3 months is 766,823 and the stock's 52-week low/high is $1.50999999/$7.19500017.

Recent News

Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2)

The QualityStocks Daily Newsletter would like to spotlight Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2).

Excellon Resources (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) is a producer of silver and base metals with precious metal exploration and development projects in Mexico, Idaho and Germany. Since its 1987 founding, the company has been advancing a precious metals growth pipeline focused on creating wealth for its stakeholders by realizing strategic opportunities in the silver and gold markets. To view the full article, visit https://ibn.fm/dgkNJ.

Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) (“Excellon” or the “Company”) is a silver and base metals producer with precious metal exploration and development projects in Mexico, Idaho and Germany. Since being founded in 1987, the Company has been advancing a precious metals growth pipeline focused on creating wealth for its stakeholders by realizing strategic opportunities in the silver and gold markets.

Excellon is an active and influential member of the Mining Association of Canada (“MAC”). The Company implements a practical, best-in-class management system that addresses the safety, health, security, environmental and community aspects of its operations, per the UN Sustainable Development Goals. On each project, the Company incorporates MAC’s Towards Sustainable Mining Initiatives and other world-class best practices with the objective of constantly improving its safety systems, training and hazard recognition.

Precious Metals Growth Pipeline

The Company is advancing a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany, with 750 years of mining history and no modern exploration.

Maintaining and developing this pipeline presents the Company with enhanced opportunities in the expanding precious metals market, which was valued at $193.3 billion worldwide in 2020 (https://nnw.fm/6nv5f). This market is expected to increase at a compound annual growth rate (“CAGR”) of 9% from 2020 to 2027, resulting in an estimated $362.1 billion market size in 2027 (https://nnw.fm/6nv5f). Global market demand was calculated at 22,581.8 tons in 2020 and is expected to grow to 36,501.1 tons in 2027, achieving a CAGR of 3.5% (https://nnw.fm/6nv5f).

Excellon reported strong results in terms of both production and average pricing at the end of Q4 2020, including:

  • Silver – 355,581 oz – $24.46
  • Lead – 2,223,465 lbs. – $0.87
  • Zinc – 2,452,728 lbs. – $1.21

Compared to Q4 2019, Excellon’s silver production increased by 37%, lead increased by 32% and zinc increased by 19% in Q4 2020 (https://nnw.fm/4C0P7).

Platosa Mine – Silver, Lead, Zinc – Production, Development & Exploration

The Platosa Mine is located 5 km north of Bermejillo, Durango, Mexico, on a 14,000-hectare property. The mine commenced production in 2005 as an underground operation and is 100% owned and operated by Excellon. The Company is mining massive sulfide ores rich in silver, lead and zinc from a series flat-lying massive sulfide bodies (mantos) in a carbonate replacement deposit system. Historically, the mining method was a modified room and pillar method, which transitioned to cut-and-fill in recent years and overhand-cut-and-bench in 2020. The ore produced from the mine is transported 200 km south for processing at the Company’s 100% owned Miguel Auza mill.

Kilgore Project – Gold – Exploration & Resource Growth

The Kilgore Project is located in Clark County, situated in eastern Idaho in the United States. The project area is 100% owned and operated by Excellon. While still in the exploration and development phase, the primary target on the 13,627-acre site is an epithermal gold system. The property itself has historical mining that dates back to the 1930s, with modern mineral exploration beginning in the 1980s. The Kilgore Project displays characteristics similar to Kinross Gold’s Round Mountain Mine, which has produced more than 15 million ounces of gold since operations began in 1977.

Evolución Project – Mineral Processing, Resource Growth & Exploration

The Evolución Project is located in Miguel Auza, Zacatecas, Mexico, and hosts a large gold, silver, lead and zinc epithermal within a 45,000-hectare property that is 100% owned by Excellon. The site includes a processing facility with a mill and flotation circuit which processes ore from Excellon’s Platosa mine. The facility has a capacity of 800 tons per day, with a 650 ton-per-day ball mill in operation and a second 150 ton-per-day ball mill on standby. Excellon is looking at opportunities for toll milling, expansion and economic study of the mineral resource and grassroots exploration. Importantly, the project covers an unexplored 35-kilometer strike of the Fresnillo silver trend, the richest silver belt in the world.

Silver City Project – Exploration

Excellon holds an option to acquire the 16,400-hectare Silver City Project in Saxony, Germany. Initial drilling results in 2020 confirmed the presence of a high-grade, district-scale epithermal silver system over more than 12 kilometers of strike. The Company is now focused on defining wider zones of mineralization (https://nnw.fm/jMah9). Silver City was mined from the 11th to late-19th century, until Germany moved off the silver standard in 1873. The deposits in the area were exceptionally high grade, with historical records indicating grades well in excess of 1,000 g/t silver.

Oakley Project – Exploration

The Oakley Project, located in Oakley, Idaho, is an exploration project with land holdings of approximately 7,000 acres. The project hosts gold-silver, epithermal hot spring-type mineralization at two targets: Blue Hill Creek and Cold Creek, and detachment-related gold-silver mineralization at Matrix Creek. The Company has granted Centerra (U.S.) Inc. an option to earn in to a 70% interest by, among other things, spending up to US$7 million in exploration expenditures on the project prior to May 2026.

Management Team

Brendan Cahill is the President & Chief Executive Officer of Excellon Resources Inc. He was previously Vice President Corporate Development of Pelangio Exploration Inc., a junior gold exploration company active in Ghana, West Africa. Mr. Cahill is a board member of the Mining Association of Canada, Group Eleven Resources Ltd., and Kore Mining Inc. He holds a law degree from the University of Western Ontario and an undergraduate degree from the University of Toronto.

Alfred Colas is the Company’s Chief Financial Officer. Most recently, he held the title of CFO of Arch Corp., a Toronto-based private-equity investment firm. Mr. Colas has over 18 years of experience in the mining industry. He is a sitting board member for a housing corporation affiliated with the University of Toronto and is a Chartered Professional Accountant. Mr. Colas completed a Bachelor of Commerce at the University of Toronto.

Paul Keller is Excellon’s Chief Operating Officer. He has over 30 years of industry experience in mining and mine development operations. He previously served as the Senior VP of Major Projects and COO of Trevali Mining. He has experience in building mines from greenfield through permitting, design and operation. Mr. Keller holds a Bachelor of Engineering – Mining from Laurentian University.

Ben Pullinger is the Senior Vice President Geology & Corporate Development for Excellon. Ben brings over 15 years of experience in advancing projects from early stage exploration through to production. Most recently, he was Vice President Exploration at Roxgold Inc., where he made a significant contribution toward growing the 55 Zone at Yaramoko Project into a producing mine. Mr. Pullinger serves on the board of Orford Mining. He is a Professional Geologist (Ontario) and holds an Honors Degree in Geology from the University of Johannesburg.

Excellon Resources Inc. (EXN), closed Thursday's trading session at $3.11, off by 4.6012%, on 28,915 volume with 200 trades. The average volume for the last 3 months is 79,594 and the stock's 52-week low/high is $2.19499993/$3.90000009.

Recent News

Ideanomics Inc. (NASDAQ: IDEX)

The QualityStocks Daily Newsletter would like to spotlight Ideanomics Inc. (NASDAQ: IDEX).

Ideanomics (NASDAQ: IDEX), on March 3, 2021, entered into an investment agreement with Energica Motor Company S.p.A pursuant to which Ideanomics invested Euro 10,909,091 for 6,128,703 ordinary shares of Energica at a subscription price of Euro 1.78 for each ordinary share. Upon purchase of the shares, Ideanomics will hold at least 20% of Energica’s share capital. For more details, visit http://ibn.fm/Q1qtS.

Ideanomics Inc. (NASDAQ: IDEX) is a global company facilitating the adoption of commercial electric vehicles and supporting next-generation financial services and fintech products. Ideanomics is currently divided into two divisions – mobility and capital. These divisions provide shareholders with access to disruptive and high-growth opportunities.

The company expects 2021 to be another growth year after it raised approximately $400 million over the past six months. This funding has already been put to good use with acquisitions of Wireless Advanced Vehicle Electrification (WAVE) and Timios. With roughly $200 million still on the balance sheet, Ideanomics continues to look for new investments and acquisitions in revenue-based opportunities focused on EV and fintech businesses.

Founded in 2004, Ideanomics is headquartered in New York, New York, with additional offices in Hangzhou, Beijing and Qingdao, China. Its current operations span the United States, China, Ukraine and Malaysia.

Ideanomics Mobility

Ideanomics Mobility is focused on the EV market. The global commercial EV market was valued at $34.7 billion in 2018 and is expected to grow at a CAGR of 39.9% through 2022 to reach a total of $132.73 billion (https://ibn.fm/pPrf4). According to a survey by Grand View Research, the global EV charging infrastructure market is also expected to grow and reach $144.97 billion in 2028, expanding at a CAGR of 33.4% from 2021 to 2028.

This growth is expected to be driven by increased support of electric vehicles from the public, as well as the current U.S. administration, which has a goal of achieving a 100% clean-energy economy.

The Ideanomics Mobility unit consists of five companies:

  • Mobile Energy Global (MEG) – Wholly owned China-based service provider of the Sales-to-Finance-to-Charging (S2F2C) business model to assist commercial fleet operators on EV enablement. Recent sales include 2,000 units of D1, BYD’s custom electric ride-hailing vehicle.
  • Medici Motor Works – Wholly owned North America division. MMW will develop zero-emissions specialty vehicles, trucks, buses and vans for the North American market.
  • Wireless Advanced Vehicle Electrification (WAVE) – Wholly owned Utah-based commercial EV charging technology company with a specialized offering of in-ground wireless charging for commercial vehicles. WAVE’s chargers power the Antelope Valley Transportation Authority, the largest municipal EV bus system in the country. Its revenue for 2020 exceeded $7 million, and it boasts a robust pipeline for 2021 and beyond.
  • Treeletrik – Majority investment in Malaysian-based OEM will service a high-demand market – electric delivery mopeds. Treeletrik has obtained certifications in Thailand and Indonesia, with orders secured for 2021. Its North American marketing program is expected to commence in 2021. As a part of the ESG initiative, one tree will be planted for every unit sold.
  • Solectrac – Minority investment in California-based electric tractor company. Solectrac manufactures 100% electric tractors to benefit farmers, crops and the planet at a time when the agriculture market remains virtually unaddressed by EV solutions.
  • Silk EV – Minority investment in hyper car and performance car design company, which provides access to the high-end battery and charging technology development ecosystem.

Ideanomics is generating EV revenue from its Sales to Financing to Charging (S2F2C) business model, which features three operating areas:

  1. Vehicle and Battery Sales: Medici, Treeletrik and Solectrac cover three key market segments
  2. Financing, Leasing and Insurance: Offering financial services to fleet customers, commission delivery and origination fee-based revenue
  3. Charging and Energy Services: Offering charging as a service, battery swap programs and WAVE wireless charging products

Ideanomics Capital

Ideanomics Capital is focused on providing disruptive fintech solutions across the entire board of financial services, ranging from financial markets to digital securities and assets to mortgages and more. More mainstream institutions and a growing number of companies have increased their digital securities services, along with institutional investments boosting bitcoin and the emergence of favorable regulatory developments, creating ample opportunities for widespread adoption of financial technologies.

Additionally, the U.S. real estate industry is ripe for technologization, as it currently is fragmented, antiquated, opaque and largely untouched by tech innovation. However, the expanding market, with U.S. home sales expected to grow 21.9% in 2021, and the increased digitization of all business spaces are expected to promote a digital-first experience as the new industry standard this year and beyond (https://ibn.fm/DwsUv).

The Ideanomics Capital unit consists of five companies:

  • Timios – Wholly owned subsidiary bringing real estate into the 21st century by providing value-add, fee-based services addressing the title and closing process of home buying and mortgage transactions. Timios works to create transparency and efficiency within the market. Timios ended 2020 as a cash flow and EBITDA positive business.
  • The Delaware Board of Trade (DBOT) – Wholly owned FINRA-regulated ATS and broker dealer based in Delaware.
  • Liquefy – Minority investment bringing innovation to investment in real assets with blockchain technology by increasing efficiency in fractional ownership, lowering entry to investment barriers and unlocking liquidity in assets that were previously illiquid.
  • Technology Metals Market (TM2) – Minority investment in UK company delivering a direct investment and trading market for technology metals with a newly accessible technology metals asset class for inventory diversification. The traded metals are 100% backed by physical metals.
  • Intelligenta – Investment providing AI and machine learning solutions for financial institutions and regulators.

Management Team

Alf Poor is Ideanomics’ Chief Executive Officer. He is a client-focused and profit-driven executive who has a track record of success in rapidly growing technology companies and large, multi-national organizations. Mr. Poor’s expertise includes business planning, financing and creating and implementing corporate governance policies, as well as handling management across organizations. His specialization is working with cross-border and multi-national startups. Before taking the CEO role at Ideanomics, he was the CEO for Global Data Sentinel.

Conor McCarthy is the company’s Chief Financial Officer. He is a strategic and operationally oriented management-level professional. His extensive international experience is within the fintech, data science and advertising technology sectors. Mr. McCarthy has experience with public companies, PE, and VC-backed firms. His specializations are financial and management reporting, planning and analysis, financial modelling, performance metrics, KPIs, venture borrowing, Series A equity funding, ERP system implementation, international business operations, and acquisition due diligence and integration. Before joining Ideanomics, Mr. McCarthy most recently held a CFO position at OS33. Prior to that, he was CFO for Intent Media Inc.

Kate Lam is the company’s Managing Director of Financial Products. She is highly regarded for her fixed income capital marketing skills across Asia and the United States. Ms. Lam has over 25 years of experience in the financial markets industry, dealing with many asset classes and clients. Having spent a few years in the fintech startup industry, her skills bridge the gap between traditional financial assets and new technological innovations. She has held senior management positions at Bear Sterns, Deutsche Bank and Standard Chartered Bank.

Keith Byers is Ideanomics’ Senior Vice President of Operations. He has extensive experience managing strategic relationships with key clients and deepening the relationships through innovation and successful engagement strategies. Before Ideanomics, Mr. Byers was the Managing Partner and Head of Operations for Gain Theory. He has a Master of Arts – MA, Economics from Heriot-Watt University and a Master of Science – Economics from The University of Edinburgh.

Tony Sklar is the company’s Senior Vice President of Investor Relations. He is a communication strategist and has worked for multi-faceted companies with global operations. Mr. Sklar handles omni-channel distribution using intelligence platforms and data insights for strategic planning, international expansion and marketing channels. His specialties include project management with digital strategy and transformation, ICO, marketing, blockchain and strategic partnerships. In addition to his role with Ideanomics, he is also a board member for the Delaware Board of Trade and the host and senior technology reporter for Far From TV.

Ideanomics Inc. (IDEX), closed Thursday's trading session at $2.86, off by 10.3448%, on 45,407,609 volume with 120,480 trades. The average volume for the last 3 months is 45,868,728 and the stock's 52-week low/high is $0.275999993/$5.5300002.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the company’s CEO, John Climaco, will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021. According to the update, CNSP management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the event. Interested parties should visit https://ibn.fm/XlGLZ for more information and to register for the conference. To view the full press release, visit http://ibn.fm/D4QcN.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Thursday's trading session at $2.25, off by 15.0943%, on 716,602 volume with 2,473 trades. The average volume for the last 3 months is 2,762,327 and the stock's 52-week low/high is $1.25820004/$5.61999988.

Recent News

VistaGen Therapeutics Inc. (NASDAQ: VTGN)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics Inc. (NASDAQ: VTGN).

VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing a new generation of medications that go beyond the standard of care for anxiety and depression. To view the full article, visit: https://ibn.fm/X5Pkn.

VistaGen Therapeutics Inc. (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (CNS) disorders.

The company is headquartered in South San Francisco, California, the “Birthplace of Biotechnology,” among the largest cluster of biotechnology companies in the world.

New Generation Medications

VistaGen currently has three innovative CNS drug candidates in its pipeline: PH94B, PH10 and AV-101. With a differentiated mechanism of action and an exceptional safety profile in all clinical studies to date, each of VistaGen’s three drug candidates offers significant commercialization potential in multiple large CNS markets.

PH94B

Fast-acting (10-15 minutes), non-systemic and non-sedating in Phase 2 clinical studies, PH94B is a first-in-class neuroactive nasal spray that, administered in microgram doses, binds to chemosensory receptors in the nasal passage that trigger neural circuits responsible for suppressing fear and anxiety caused by stressful social or performance situations.

PH94B is currently being developed as an acute treatment of anxiety in adults with Social Anxiety Disorder (SAD). In December 2019, PH94B became the first drug candidate to be granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for development of a treatment for SAD, positioning it to potentially become the first FDA-approved fast-acting acute treatment for adults with the anxiety disorder, if planned Phase 3 studies are successful.

A successful Phase 2 program has been completed, and, after achieving consensus with the FDA in mid-2020 that the design of its Phase 3 studies of PH94B in SAD may mirror the design of the highly statistically significant (p=0.002) Phase 2 public speaking study of PH94B in SAD, the company’s preparations for pivotal Phase 3 clinical development of PH94B are underway.

To support Phase 3 development and commercialization of PH94B for anxiety disorders in large anxiety disorder markets in Asia, VistaGen recently entered into a strategic licensing and collaboration agreement with EverInsight Therapeutics, a company formed and currently funded by a large global venture capital firm, CBC Group. The company received a $5 million non-dilutive upfront license payment from EverInsight in August 2020. If Phase 3 development is successful, VistaGen is eligible to receive additional development and commercial milestone payments of up to $172 million, plus tiered royalties on sales of PH94B in Greater China, South Korea and Southeast Asia. VistaGen retains exclusive rights to develop and commercialize PH94B in all other markets.

VistaGen is also assessing potential Phase 2A clinical development opportunities to evaluate PH94B in a range of other anxiety disorders, including:

  • Adjustment Disorder with Anxiety
  • Generalized Anxiety Disorder
  • Postpartum Anxiety
  • Perioperative Anxiety
  • Panic Disorder
  • PTSD

PH10

PH10 is an investigational fast-acting synthetic neuroactive nasal spray with therapeutic potential in a wide range of neuropsychiatric indications involving depression and suicidal ideation. VistaGen is initially developing PH10 as a potential fast-acting, non-sedating, non-addictive new generation treatment of major depressive disorder (MDD).

Upon self-administration, a microgram-level dose of PH10 sprayed into the nose binds to nasal chemosensory receptors that, in turn, activate neural circuits in the brain that lead to rapid-onset antidepressant effects, without side effects, systemic exposure or safety concerns that may be caused by FDA-approved drug treatments for MDD, including oral antidepressants and intranasal esketamine.

In a published exploratory Phase 2A MDD study, PH10 demonstrated rapid-onset and sustained antidepressant effects without the serious psychological side effects and safety concerns of ketamine-based therapy.

Following successfully completed Phase 2A development of PH10 for MDD, the company is currently preparing for a Phase 2B program in MDD.

VistaGen is also assessing the potential for Phase 2A clinical development of PH10 in a range of other depression-related indications, including:

  • Postpartum Depression
  • Treatment-resistant Depression
  • Suicidal Ideation

AV-101

Part of a class of new generation investigational medicine in neurology and neuropsychiatry known as N-methyl-D-aspartate receptor (NMDAR) modulators, AV-101 is an oral prodrug of 7-chloro-kynurenic acid (7-Cl-KYNA), a potent and selective NMDAR glycine site antagonist. This drug candidate has the potential to serve as an innovative treatment for MDD and multiple neurological indications where current therapies are unsatisfactory.

VistaGen is currently evaluating AV-101, in combination with FDA-approved probenecid, in a range of neuropsychiatric and neurological indications, with both MDD and Neuropathic Pain already granted Fast Track designation by the FDA. The company is assessing the combination for a potential Phase 1B study to support a potential Phase 2A program in one or more of the following indications:

  • Major Depressive Disorder
  • Neuropathic Pain
  • Levodopa-induced dyskinesia associated with Parkinson’s disease therapy
  • Epilepsy
  • Suicidal Ideation

CNS Therapeutics Market Outlook

The global CNS therapeutics market is estimated to reach $130 billion by 2025. The market was valued at approximately $82.3 billion in 2017 and is anticipated to grow at a healthy CAGR of more than 5.93% from 2018 to 2025. Even before the onset of the anxiety- and depression-provoking stressors from the COVID-19 pandemic, this growth was expected to be driven by a rise in mental illnesses and increased awareness of psychiatric disorders (https://nnw.fm/K2m0s) – all likely to be amplified by the diverse impacts of the pandemic.

The two most common mental health conditions – anxiety and depression – cost the global economy an estimated $1 trillion each year. The impact of these conditions is particularly devastating among the young. Industry data suggest that approximately 20% of the world’s children and teens are affected by mental health conditions, and suicide is the leading cause of death among 15- to 29-year-olds (https://nnw.fm/oftNb).

VistaGen’s mission is to help address the unmet needs of patients suffering from CNS disorders whose current treatments are either inadequate or generate debilitating side effects and serious safety concerns, including risk of abuse and death.

“Now more than ever, the new generation anti-anxiety and antidepressant medications we are developing at VistaGen – PH94B, PH10 and AV-101 – are relevant, necessary and demand the highly-focused and passionate efforts of our team and partners, with the support of our stockholders, to advance them to patients whose lives are disrupted by anxiety and depression disorders,” VistaGen CEO and Director Shawn K. Singh said in his closing remarks at the company’s 2020 Annual Meeting of stockholders.

Management Team

Shawn K. Singh, J.D. is the Chief Executive Officer and a Director of VistaGen. He has served on the company’s board of directors since 2000. He has nearly 30 years of experience serving in numerous senior management roles across multiple industries, including private and public biotechnology, pharmaceuticals, medical devices, venture capital, contract research and development, and law. Singh has a B.A. with honors from the University of California – Berkley. He has a J.D. degree from the University of Maryland Carey School of Law. He is also a member of the State Bar of California.

H. Ralph Snodgrass, Ph.D., is the Founder, Chief Scientific Officer and Director of the company. Snodgrass has more than 20 years of experience in the biotechnology field as a senior manager. He is recognized as an expert in stem cell biology, with over 28 years of experience using stem cells as biological research tools to promote development and drug discovery. He received a Ph.D. in immunology from the University of Pennsylvania. Snodgrass has published over 50 scientific papers with more than 17 patents and a number of patent applications.

Mark A. Smith, M.D., Ph.D., is VistaGen’s Chief Medical Officer He has over 20 years of pharmaceutical industry experience, primarily with CNS drug development. Smith has been a successful leader in the discovery and development of approximately 20 investigational new drugs. He has been a part of numerous CNS-related clinical trials. Smith received a bachelor’s and Master of Science from Yale University and a Doctor of Medicine and Doctor of Philosophy in Physiology and Pharmacology from the University of California – San Diego. He completed his residency in the psychiatry department at Duke University Medical Center.

Jerrold D. Dotson, CPA, is the Vice President, Chief Financial Officer and Secretary of VistaGen. He has over 25 years of experience in senior management positions in finance and administration at both public and private companies. Dotson is a licensed CPA in California and received his B.S. degree (Cum Laude) in business administration with a concentration in accounting from Abilene Christian College.

Mark A. McPartland is the company’s Vice President of Corporate Development and Investor Relations. He has over 20 years of experience in senior management roles in corporate development and investor relations at both public and private companies. McPartland received his Bachelor’s in business administration and marketing from Coastal Carolina University.

VistaGen Therapeutics Inc. (NASDAQ: VTGN), closed Thursday's trading session at $2.20, off by 5.1724%, on 3,596,097 volume with 11,990 trades. The average volume for the last 3 months is 4,444,879 and the stock's 52-week low/high is $0.300000011/$3.18000006.

Recent News

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT)

The QualityStocks Daily Newsletter would like to spotlight XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT).

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, announced that it has completed its corporate rebranding efforts. Those efforts included the launch of a completely redesigned website. To view the full press release, visit http://ibn.fm/bvd1D.

XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. This includes products that are being readied for commercialization within the coming weeks, such as a rapid COVID-19 PCR test kit that reduces turnaround times to less than 30 minutes.

The company has research and development operations in North America and Europe and an operational focus in Germany. Its regulatory approval and commercialization focus is currently on products for the European market.

XPhyto was founded in 2017 and is headquartered in Vancouver, British Columbia.

Business Strategy & Milestones for 2021

On January 18, 2021, XPhyto issued a news release detailing its business strategy for the coming year. The company noted that it is “on the cusp of transformational change as product development programs advance from the laboratory to the clinic.” In addition to continuing to leverage its scientific expertise and operations in North America and Europe for product development and optimization, XPhyto intends to pursue growth through the commercialization of existing products and adherence to a focused investment strategy targeting impact-driven innovation with “the potential for extreme value creation.”

In particular, XPhyto is well positioned to execute on opportunities across its current business divisions, including:

  • Commercialization of infectious disease diagnostics
  • Clinical validation of transdermal and sublingual drug formulations
  • Continued investment and development in psychedelic medicine

“2020 was a very productive year for XPhyto. We made significant progress in all areas of our business,” Hugh Rogers, CEO & Director of XPhyto, stated in the update. “We have ambitious milestones for 2021 with multiple product launches on the horizon, multiple clinical drug programs underway, and an aggressive commitment to psychedelic medicine. I am extremely confident that our team can execute on the company’s business plan for 2021.”

Infectious Disease Diagnostics

XPhyto’s lead diagnostic product, secured through an exclusive global commercialization agreement with 3a-diagnostics GmbH (“3a”), is a rapid and highly portable PCR diagnostic test. Notably, PCR testing “has emerged as the only internationally recognized standard for COVID-19 testing” and is expected to play a key role in facilitating the recovery of the domestic and international travel industries, among others.

Successful validation of the PCR system was achieved in Q4 2020, and XPhyto has expressed confidence that it will achieve European commercial (CE-IVD) approval in Q1 2021. In preparation for this milestone and an anticipated Q1 product launch, the company is currently in discussion with manufacturing and distribution partners in Europe and the Middle East.

In addition to COVID-19 products, XPhyto and partner 3a are developing and commercializing a portfolio of low-cost oral biosensors. The company’s lead biosensor product is an oral health screening test for the detection of peri-implantitis for which XPhyto is targeting a late 2021 European commercial approval.

XPhyto does not make any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.

Drug Formulation & Delivery

In 2020, XPhyto’s German subsidiary, Vektor Pharma TF GmbH (“Vektor”), reported significant advancement in four therapeutic programs targeting neurological indications with significant market demand. Vektor also successfully developed a sublingual drug formulation on contract for a major generic drug manufacturer and distributor.

XPhyto will look to build on this progress in 2021, with plans to complete human pilot studies evaluating its four lead therapeutic products:

  • Rotigotine transdermal patch for Parkinson’s disease
  • CBD oral/sublingual strip for treatment resistant epilepsy
  • THC oral/sublingual strip for anorexia/nausea
  • CBD:THC (1:1) oral/sublingual strip for multiple sclerosis associated spasticity

Per its 2021 business update, the company is currently in “ongoing discussions with multiple potential commercial partners, licensors and distributors and will be reviewing monetization opportunities on a continued basis.”

Psychedelic Medicine

Psychedelic compounds are a highly promising new class of active pharmaceutical ingredient (“API”) demonstrating strong potential for a variety of mental health conditions. XPhyto is positioned to capitalize on this promise through two strategic initiatives:

  • An agreement for the development of industrial scale biotechnology processes for the production of psilocybin
  • An agreement for R&D related to multiple psychedelic compounds, including psilocybin, mescaline, LSD, MDMA and DMT, among others

XPhyto intends to advance and expand its programs focused on the industrial scale production of psychedelic API in 2021. The company also plans to launch new programs for the development of psychedelic drug formulations, with a focus on sublingual and transdermal therapeutics and the integration of these products into established clinical programs relating to mental health indications.

Management Team

Hugh Rogers is the CEO and Director of XPhyto Therapeutics Corp. He is an entrepreneur and lawyer with private and public start-up company experience in various industries and operational roles. His recent advisory work has focused on public listings and corporate restructuring. This restructuring has occurred in the life science (cell therapy and medical device) and natural resources (natural gas co-gen and conventional oil) industries. Mr. Rogers holds a bachelor’s degree in Cellular Biology and Genetics and a law degree. He is a member in good standing of the Law Society of British Colombia.

Christopher Ross is the CFO of XPhyto. He is a professional accountant with broad financial experience across numerous industries, including forestry, distribution, construction, mining and multi-family real estate. He has provided advisory services to private and public companies in the areas of financial accounting, strategic analysis, audit and taxation. Mr. Ross holds a bachelor’s degree in commerce. He is a member in good standing with the Chartered Professional Accountants Association of British Columbia.

Wolfgang Probst serves as Director of XPhyto and Managing Director of BUNKER Pflanzenextrakte GmbH. He is a seasoned management and financial consultant based in Bavaria, Germany. He has consulting experience as branch head working with private clients and corporations of high net worth. In 2017, Mr. Probst assumed the CFO role of BUNKER and continues to play a key role in its operational and financial development.

Professor Dr. Raimar Löbenberg serves as Director of XPhyto. He holds a Bachelor of Science in pharmacy from Johannes Gutenberg-University and a Ph.D. in pharmaceutics from the Johann Wolfgang Goethe-University. He is the co-founder of RS Therapeutics Inc., which concentrates on foam-based topical drug delivery systems.

Professor Dr. Thomas Beckert is the Founder and Managing Director of Vektor Pharma TF GmbH. His expertise includes the formulation and machine development of transdermal therapeutic systems and ODFs. Professor Beckert holds a Bachelor of Science in pharmacy from the University of Freiburg and a Ph.D. in pharmacy and economics from the University of Tubingen.

XPhyto Therapeutics Corp. (OTCQB: XPHYF), closed Thursday's trading session at $2.16, off by 7.2961%, on 74,027 volume with 259 trades. The average volume for the last 3 months is 70,535 and the stock's 52-week low/high is $1.3125/$3.0999999.

Recent News

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences (OTCQB: PBIO) ("PBI") founder, president and CEO Ric Schumacher was a guest on a recent episode of “Emerging Technology Insider,” which regularly releases video conversations with management of technology companies with business or financial objectives. During the interview, Schumacher focused on the company’s recently announced food industry consortium partnership with The Ohio State University and the impact it may have on the food industry. To view the full press release, visit http://ibn.fm/cMHra

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions — all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Thursday's trading session at $2.10, off by 2.3256%, on 19,079 volume with 50 trades. The average volume for the last 3 months is 23,386 and the stock's 52-week low/high is $1.19000005/$4.48999977.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CLXPF)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (OTC: CLXPF).

Cybin Inc. (NEO: CYBN) (OTC: CLXPF) was featured today in a publication from PsychedelicNewsWire, examining how the development of a new class of pharmaceutical medications made from psychedelic fungi and plants has brought medical science closer to making breakthroughs that address the global mental health crisis caused by the pandemic. These drugs have shown massive potential in the treatment of chronic depression. However, there are challenges that come with the development of standardized organic compounds to help treat more than a billion individuals globally for various mental health conditions.

Cybin Inc. (NEO: CYBN) (OTC: CLXPF) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (OTC: CLXPF), closed Thursday's trading session at $1.1927, off by 2.732%, on 640,374 volume with 590 trades. The average volume for the last 3 months is 462,972 and the stock's 52-week low/high is $0.0284/$2.23499989.

Recent News

Brain Scientific Inc. (OTCQB: BRSF)

The QualityStocks Daily Newsletter would like to spotlight Brain Scientific Inc. (OTCQB: BRSF).

Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company focused on developing innovative and proprietary medical devices and software, is working on developing state-of-the-art AI diagnostic analytics. The company’s two FDA-cleared products — the NeuroCap(TM) and NeuroEEG(TM) — offer cost-effective disposable alternatives to existing electroencephalogram (“EEG”) solutions. These disposable and simple-to-use devices allow medical professionals to collect necessary diagnostic information quickly.

Brain Scientific Inc. (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. With a mission of modernizing brain diagnostics by employing cutting edge technologies to bridge the widening gap in access to quality care, the company offers two FDA-cleared products that provide next-generation solutions to the neurology market.

The company’s proprietary, clinical-grade neurological devices are supported by its intellectual property portfolio featuring patents in the United States, China and Europe.

Brain Scientific’s first commercialized devices, NeuroCap(TM) and NeuroEEG(TM), are designed to disrupt the current electroencephalogram (EEG) market by offering cost-effective and disposable substitutes to existing solutions, allowing medical professionals to collect diagnostic information quickly.

The company’s goal is to improve diagnostics by leveraging artificial intelligence and machine learning processes to analyze a database of brain readings as a method of detecting seizures and dementia. The company is also working to improve patients’ access to neurological care.

Headquartered in New York, Brain Scientific and its predecessor (and now wholly owned subsidiary, MemoryMD Inc.) was founded in 2015 and went public in 2018.

Brain Scientific’s first phase of development, from 2018 to 2019, saw the inception of portable, clinical-grade, easy-to-use neurological devices. The second phase, currently ongoing, aims to create cloud-based, secure infrastructure to transmit patient data between patients and their neurologists. The company’s third phase of development is scheduled for 2021-2022 and is expected to focus on the use of AI-assisted diagnostic analysis to increase the efficiency, consistency and accuracy of neurology specialists.

NeuroCap(TM) – Disposable EEG Headset

The NeuroCap is a disposable pre-gelled EEG headset featuring 22 electrodes and 19 active EEG channels, all adhering to the international 10-20 system. The NeuroCap was FDA-cleared in 2018. The headset can be used for recording EEGs in virtually any setting, including urban and rural emergency departments, neurology clinics, urgent care clinics, ICUs, nursing homes, assisted living facilities and remote clinical research labs.

Through a universal cable adapter, the NeuroCap is compatible with other EEG amplifiers. The cap also works in parallel with Brain Scientific’s NeuroEEG amplifier, initiating EEG studies in less than five minutes.

The company is currently seeking FDA approval for additional features for the NeuroCap, as the device has the potential to fill a gap in EEG testing availabilities during the current coronavirus pandemic: in October 2020, Brain Scientific filed an Emergency Use Authorization (EUA) application. The EUA is required for the rapid distribution of the NeuroCap device to emergency departments, intensive care units and other treatment centers to administer prescriptive EEGs safely on critically ill patients or those suspected of being diagnosed with COVID-19.

With more than 80 percent of hospitalized patients infected with COVID-19 displaying neurological symptoms, the NeuroCap could prove to be a valuable device by offering fast testing with limited contact between technicians and patients.

NeuroEEG(TM) – Miniature and Portable Wireless EEG Amplifier

The NeuroEEG is a compact, portable and affordable wireless EEG amplifier intended for prescription use. The 16-channel, FDA-cleared, clinical-grade device acquires, records, transmits and displays electrical brain activity for patients of all ages.

Both the NeuroCap and NeuroEEG are delivered by MemoryMD Inc., a wholly owned subsidiary of Brain Scientific.

Products in Active Development

Currently, Brain Scientific and MemoryMD are working on leveraging their existing products and drawing from ongoing research to develop and commercialize the next generation of solutions for the brain diagnostics market. The devices under development are being designed to address the following issues:

Routine EEG

  • NeuroCap-8 is an 8-channel EEG cap. The reduced number of electrodes is vital in emergency room situations, where the time it takes to set up the EEG is critical.

Pediatric EEG

  • NeuroCap Pediatric is positioned to become the first disposable and pre-gelled headset available for the pediatric market.

Long-Term Monitoring

  • NeuroCap LTM for adult and pediatric patients is a disposable cap designed to monitor rhythmic and periodic patterns for up to 72 hours, providing essential diagnostic capabilities.
  • NeuroEEG 24 Channel Amplifier is a portable and wireless amplifier with over 24 hours of battery life.

Artificial Intelligence

  • Brain E-Tattoo is a minimally invasive four-channel EEG electrode designed for long-term monitoring.
  • An AI database of brain biomarkers collects data on both normal and abnormal brain data to detect neurological diseases. The goal is for machine learning algorithms to enhance understanding of brain-behavior related to epilepsy, memory dementia and pre-Alzheimer’s diagnostics.

Telemedicine

Brain Scientific is expanding the vision for telemedicine in neurology. The company aims to address the current acute neurologist shortfall (20 states have less than 10 neurologists per 10,000 patients) through the use of teleneurology.

 

Partnership with Marketing Brainology

Brain Scientific has a longstanding partnership with Marketing Brainology, a neuromarketing firm using neuroscience approaches to understand consumer behavior. In 2019, Marketing Brainology conducted a study using NeuroCap and NeuroEEG to determine the most effective Super Bowl commercials.

“Thanks to Brain Scientific’s NeuroCap and NeuroEEG, we are able to better understand the art and science of the human decision-making process,” Michelle Adams, Ph.D, Founder of Marketing Brainology, stated in a news release.

In April 2020, Marketing Brainology again conducted a study leveraging Brain Scientific’s disposable EEG cap to determine how brains were reacting to COVID-19 messaging. Subjects were presented with multiple media impressions, and Marketing Brainology analyzed their responsive biomarkers. The results identified the most effective messaging for engaging with an audience during a crisis.

Market Outlook

The current global market for EEG devices is estimated at $956.1 million. It is expected to rise with a CAGR of 8.7% from 2019 to 2026, reaching $1.6 billion in value by 2026, according to Grandview Research.

In total, there are approximately 6,150 hospitals in the U.S., according to the American Hospital Association. Critically, though, just 254 of those hospitals are certified Level 4 Epilepsy centers with 24/7 EEG coverage. Since very few non-Level 4 centers have extensive EEG tech coverage, this creates a significant opportunity for Brain Scientific to bridge the gap by providing over 5,900 hospitals with lower cost amplifiers and disposable EEG caps.

The company also see opportunities to work with other businesses, such as EEG manufacturers hoping to package Brain Scientific’s solutions with their products, which could greatly expand Brain Scientific’s addressable target market.

Management Team

Dr. Baruch “Boris” Goldstein, Ph.D., is co-founder and Chairman of Brain Scientific. He is a seasoned executive with a proven talent for aligning global business strategies with established and emerging management teams. Goldstein’s growth-focused leadership style has helped him raise over $750 million in venture capital for the development of innovative companies and startups in diverse industries, including financial services, biomedicine, alternate energy and new materials, as well as groundbreaking work in artificial intelligence. His recent achievements include important advancements in neurology and unlocking the potential of AI correlations and machine learning applied to life sciences and medical research. He built a suite of first-to-market companies as a technology-oriented leader, including Ryah Medtech, Brain Scientific, GrapheneCA, E-Forex and Intelligent Video Systems. He also co-founded BrainRX, a company specializing in pre-Alzheimer’s diagnostics.

Dr. Nikolay Kukekov, Ph.D., is a Director of Brain Scientific and a partner at HRA Capital. Before joining HRA Capital, Kukekov was Managing Director of Healthcare Investment Banking at Summer Street Research. His scientific background includes a bachelor’s degree in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder. He earned his Ph.D. in neuroscience from Columbia University – College of Physicians and Surgeons in New York.

Stuart Bernstein is the company’s Vice President of Marketing. He was recently named to the role after spending the first part of his professional career in senior technical management roles with Fortune 500 companies such as NCR (NYSE: NCR), IBM (NYSE: IBM) and Control Data Corp. He was the CEO of BioSignal, an EEG medical device company. He is also a co-founder of several software engineering and telemedicine firms. One of them, Brain Saving Technology, is now Specialist on Call (SOC Telemed) – a leading telemedicine company that powers over 850 facilities for teleneurology, telepsychiatry and critical care telemedicine with over 200 physicians.

Brain Scientific Inc. (OTCQB: BRSF), closed Thursday's trading session at $1.45, off by 3.3333%, on 2,991 volume with 7 trades. The average volume for the last 3 months is 9,443 and the stock's 52-week low/high is $0.100000001/$3.00999999.

Recent News

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF)

The QualityStocks Daily Newsletter would like to spotlight Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF).

Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF), an investment company, and its investee company PowerTap Hydrogen Fueling Corp. have announced their support for a recent announcement made by the city of Petaluma, California. The city has banned new gas stations in a move designed to encourage the deployment of hydrogen fueling and battery electric charging stations, a move that Clean Power Capital and PowerTap applaud. To view the full press release, visit http://ibn.fm/QA4MF.

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) is an investment holding company that focuses on investing in and providing early-stage financing to both public and private businesses. Since its original listing with the Canadian Stock Exchange (“CSE”) on January 23, 2019, the company has made investments in a number of different businesses in a variety of industries, including the energy and cannabis sectors. As per the company’s investment policy, its primary goal is to identify and capitalize on high-return investment opportunities presenting the ability to achieve capital appreciation and liquidity.

Clean Power Capital continues to be opportunistic in evaluating prospects across the renewable energy, bio-medical, pharmaceutical and naturopathic sectors, both as an investor and as an operator. The company’s main focus at the moment is to identify such opportunities in the renewable energy industry, including wind, solar and geothermal power and hydrogen and fuel cell technologies, as well as in the biomedical, pharmaceutical and naturopathic sectors, which may include medical or recreational cannabis.

Clean Power Capital currently has 10 investments in a variety of sectors and successfully held nearly C$120 million in investments during the past fiscal year (https://ibn.fm/8oktZ). It returned capital to its shareholders through the distribution of its interest in AgraFlora Organics International Inc. in May 2020 (https://ibn.fm/FRAvq).

Headquartered in Vancouver, British Columbia, Clean Power Capital was formerly named Organic Flower Investments Group Inc. As of November 10, 2020, the company officially changed its name to Clean Power Capital and started trading on the CSE under new ticker symbol ‘MOVE’.

PowerTap Acquisition, Hydrogen Fueling Infrastructure Collaboration

In alignment with its updated investment policy, a reconstituted investment committee and a revised strategy to reflect its focus on the renewable energy market, Clean Power Capital recently completed the acquisition of a 90 percent equity interest in California-based PowerTap Hydrogen Fueling Corp.

Leveraging an impressive portfolio of IP and advanced deployed technologies developed over two decades via substantial investments and partnerships, PowerTap is working on building and expanding a hydrogen filling station network, initially across North America. The company believes that its platform has a significant advantage over other hydrogen fueling stations, because it has a smaller physical footprint and further has the capacity to produce hydrogen fuel on site. As most other hydrogen fueling stations buy hydrogen for storage at higher costs, PowerTap’s model is believed to be exponentially more cost-effective and expandable.

Clean Power Capital’s investment and acquisition will allow PowerTap to step up its efforts and begin work on the hydrogen fueling station network in stages, starting with engineering and design, ongoing development of PowerTap’s third generation product and, finally, licensing & permitting and site preparation. Development is expected to begin in Q4 2021 with engineering and design. Overall, the initial portion of the project is expected to cost $17 million, with Clean Power Capital and PowerTap planning to secure government financing and credit, as well as equity, debt and convertible debt offerings, to fund the infrastructure’s development.

PowerTap technology is already deployed across multiple hydrogen fueling stations in public and private enterprises spanning California, Maryland, Massachusetts and Texas. The company plans to deploy its hydrogen fueling infrastructure at existing truck stops and gas stations across the country, beginning with up to 1,000 stations within the next three to five years. At the moment, there are roughly 70 active hydrogen fueling stations operational and available to consumers in the United States.

Hydrogen Industry Outlook

The project is expected to bring significant opportunities for PowerTap and Clean Power Capital on the fast-growing hydrogen market, driven by a worldwide focus on clean energies and environmentally friendly fueling solutions for the transportation industry.

Hydrogen-powered vehicles come with tremendous advantages over gas, diesel and even electric vehicles in terms of cost per mile, fueling time and driving range, as well as boasting significantly lower emissions. Well-established vehicle manufacturers such as Hyundai, Toyota, Daimler and Volvo are already including hydrogen-powered cars in their product lineups, and Nikola Motors has announced plans to manufacture hydrogen electric long-haul vehicles.

“As an experienced developer of technology in an important area that is finally having its time as a green but also economically compelling energy option, PowerTap is intent on becoming a leading part of the multi-billion dollar hydrogen fueling space,” PowerTap CEO Raghu Kilambi explained in a news release on October 28, 2020 (https://ibn.fm/oaXem).

A recent industry report developed by a coalition of major oil and gas, power, automotive, fuel cell and hydrogen companies indicates that the sector is expected to grow to $140 billion a year in revenue by 2030, creating 700,000 jobs in the U.S. alone (https://ibn.fm/UMI5q). According to Fuel Cell and Hydrogen Energy Association President Morry Markowitz, the sector could expand to $750 billion a year in revenue and 3.4 million jobs by 2050.

The U.S. is already engaged in the hydrogen economy, having more than half of the global number of fuel cell vehicles and investing hundreds of millions of dollars a year, but the country can greatly expand its global energy leadership by scaling up operations in the hydrogen economy, per the industry report.

With the upcoming change in administration in January 2021, the U.S. is expected to renew its commitment to clean energy. Moreover, the U.S. federal government is expected to invest significantly in clean energy and related infrastructure, including hydrogen, according to PowerTap.

“As the U.S. federal government has previously invested in the PowerTap technology, we are optimistic that we will have a seat at the table when USA clean energy/hydrogen infrastructure spending initiatives are designed,” Kilambi added.

Management Team

Joel Dumaresq is the CEO and interim CFO of Clean Power Capital. He is a proven executive with extensive operational and senior management experience in mining, energy and alternative energy, as well as the cannabis and hemp space. Dumaresq began his career in the corporate finance space, having spent 12 years with RBC Dominion Securities. He brings 30 years of experience in the financial sector to the company, has been instrumental in raising over $250 million in venture capital finance, and he has personally managed a number of successful public listings.

Brendan Purdy serves as a director of Clean Power Capital. An experienced businessperson who has led five different companies, Purdy brings years of experience in different industries, including cannabis, blockchain and data security, gaming, mining and energy, and finance and law. He received a graduate degree from the University of Ottawa and an undergraduate degree from the University of Western Ontario.

Theo van der Linde serves as a director of Clean Power Capital. He is a Chartered Accountant with over 20 years extensive experience in finance, reporting, regulatory requirements, public company administration, equity markets and financing of publicly traded companies. He has served as a CFO & Director for a number of TSX Venture Exchange- and Canadian Securities Exchange-listed companies over the past several years. His industry experience spans the financial services, manufacturing, oil & gas, mining and retail industries. More recently, van der Linde has been involved with future use trends of natural resources, as well as other disruptive technologies.

Raghu Kilambi is the CEO and CFO of PowerTap Hydrogen. He is a seasoned investor and entrepreneur with over 25 years of global business experience in public and private investments, building businesses and creating shareholder value. He has raised over $1 billion of equity and debt capital for private and public companies and been involved in many M&A acquisitions and exits.

Clean Power Capital Corp. (OTC: MOTNF), closed Thursday's trading session at $1.42, off by 7.7922%, on 131,954 volume with 188 trades. The average volume for the last 3 months is 215,047 and the stock's 52-week low/high is $0.0315/$2.78999996.

Recent News

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company focused on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has been a forerunner in the field, helping oncologists individualize cancer treatment through its Helomics division. To view the full article, visit: https://ibn.fm/qGVfn

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Thursday's trading session at $1.25, off by 18.8312%, on 4,901,607 volume with 9,962 trades. The average volume for the last 3 months is 4,402,962 and the stock's 52-week low/high is $0.629999995/$4.42000007.

Recent News

The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER)

The QualityStocks Daily Newsletter would like to spotlight The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER).

The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) has announced that its Alkaline88(R) line of  bottled water will soon be available in Mexico through Tiendas Sindicales, a superstore grocery chain based in Mexico; Tiendas Sindicales is also a food service and vending service provider. WTER partnered with Tiendas Sindicales to enter Mexico, which is one of the largest bottled water markets in the world; the country reported a per capita consumption of 73.7 gallons in 2019, with eight out of 10 Mexican citizens regularly consuming bottled water. To view the full press release, visit http://cnw.fm/4YYT5

Founded in 2012, The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88®, is a leading premier alkaline water brand available in bulk and single-serve sizes, along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88® delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts the company’s trademarked label ‘Clean Beverage’. Quickly being recognized as a growing lifestyle brand, Alkaline88® launched A88 Infused™ in 2019 to meet consumer demand for flavor-infused products. A88 Infused™ flavored water is available in six unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched the A88CBD™ brand, featuring a broad line of topical and ingestible products. These products are made with lab-tested full and broad-spectrum hemp and include salves, balms, lotions, essential oils, bath-salts, CBD infused drinks, tinctures, capsules, gummies and powder packs.

Innovation and Expansion

Founded in 2012, The Alkaline Water Company began with a mission to create the best-tasting water in the world. At the time, there were two emerging trends in health-conscious consumers: a growing interest in the alkaline diet and perceived health benefits of pink Himalayan rock salt. By combining these two concepts in an alkaline water and trademarking the name Alkaline88, The Alkaline Water Company began offering what it calls the smoothest tasting Clean Beverage™ in the U.S. enhanced-water category.

Now a top bulk alkaline-water brand (the company reported record sales in March and April 2020, surpassing March and April 2019 numbers by 114% and 171%, respectively), The Alkaline Water Company is committed to growing its national footprint through innovation and expansion. That mindset was evident as the company introduced eco-friendly aluminum bottles and branched out into flavor-infused waters; the company currently offers six different flavors: peach/mango, lemon/lime, raspberry, watermelon, blood orange and lemon.

The company’s commitment to innovation may be most evident in its newest product line: A88CBD. This line of CBD-infused products includes tinctures, capsules, gummies, salves, balms, hand and foot lotions, essential oils, bath bombs and bath salts, as well as CBD-infused drinks, water and beverage shots. These quality, CBD-infused offerings are all made with lab-tested, full-spectrum hemp and are conveniently packaged and perfect for on-the-go or at home use.

In addition, The Alkaline Water Company has implemented an aggressive growth strategy, with numerous organic initiatives focused on national multichannel, mass-market expansion through a direct-to-warehouse model and co-packing facilities that are strategically located within 600 miles of 95% of the U.S. population. In addition to this strong brick-and-mortar approach, the company recently launched a B2C e-commerce platform (www.A88CBD.com) and aggressive digital-marketing campaigns.

Clear Advantages in a Growing Market

With consistent growth year over year, the company reported $32.2 million in revenue in fiscal 2019 and has emerged as a growth leader in the functional (value-added) waters space, which is the fastest-growing segment of the bottled water industry.

The Alkaline Water Company’s efforts are focused on its clear competitive advantages, including its strong marketing (the inclusion of alkaline in product names); existing grocery channels, which feature excellent relationships and a nationwide broker network; distinctive branding; proprietary technology, which produces great-tasting, high-quality water, infused drinks and other products; and price, with a broad range of products in all formats, from bulk bottles to single serve.

As the company focuses on strategic growth, it is eyeing the impressive potential of a market that is on a strong upswing. Annual bottled water sales have now surpassed soda consumption, with soda sales in the United States having declined by $1.2 billion over the past five years. Some research indicates that the global bottled water market will reach an estimated $280 billion this year, while the CBD market is forecast to top $20 billion by 2024.

With its products available in all major trade channels, including grocery stores, drug stores, c-stores and big-box retailers, The Alkaline Water Company is also looking to expand into new spaces, such as health and beauty, hospitality and specialty retailer locations.

Seasoned Management Team

The Alkaline Water Company is led by an experienced team focused on the company’s core strategy of building a national retail footprint and extending its lifestyle brands into other consumer packaged goods categories.

Richard A. Wright, President, CEO and Co-Founder of The Alkaline Water Company Inc., oversees all aspects of the business, successfully guiding the company through strategic opportunities and delivering greater than 50% growth since the company’s inception. A passionate and versatile leader with a strong track record of innovation, collaboration and achieving goal-driven results, Wright is a serial entrepreneur with more than 41 years of experience. Early in his career, he spent years at one of the ‘Big Four’ accounting firms, working his way up to Regional Director of Tax and Financial Planning. As a CPA, entrepreneur and former CFO, Wright brings extensive knowledge of finance, operations, sales and marketing to the team, and he has participated in hundreds of M&A transactions throughout his career.

David Guarino, CFO, Secretary, Treasurer and Director, earned a Bachelor of Science in accounting and a Master of Accountancy from the University of Denver. From 2008 to 2013, Guarino was President and a Director of Kahala Corp., a worldwide franchisor of multiple quick-service restaurant brands with locations in 49 states and more than 25 countries. From 2014 to 2015, Guarino was President of HTI International Holdings Inc., a technology company focused on forward osmosis water filtration technology.

Frank Chessman, National Sales Manager, is a graduate of the University of Southern California’s Marshall School of Business. He spent 25 years with Ralph’s Grocery, Kroger’s largest division, working at many levels before ultimately becoming Vice President of Advertising & Marketing. He then served 14 years as Executive Vice President at Simon Marketing. Chessman has more than a decade of experience in the beverage manufacturing industry.

Brian Sudano, Director, is managing partner of Beverage Marketing Corporation and BMC Strategic Associates. Sudano’s experience covers nearly the entire beverage industry, from energy drinks to wine, with special expertise in beverage alcohol by virtue of varied industry experience across a broad range of projects. Sudano manages several major clients, providing ongoing strategic and market advice and leading projects in strategic planning, market entry analysis and planning, sales/distribution, business modeling, brand repositioning and international opportunity assessment. He has spoken at many beverage industry events and is a contributing editor at Beverage World magazine.

Aaron Keay, Chairman, has been a successful investor, entrepreneur and financier to multiple small cap and startup companies over the last decade. During his time with these companies, he served in advisor, board-member and senior-management roles. His experience ranges across multiple sectors in mining, biotech, health and wellness, tech and cannabis, where he has invested and raised more than $500 million.

The Alkaline Water Company Inc. (NASDAQ: WTER), closed Thursday's trading session at $1.12, off by 4.2735%, on 2,848,969 volume with 5,027 trades. The average volume for the last 3 months is 2,249,433 and the stock's 52-week low/high is $0.400000005/$2.5999999.

Recent News

Green Hygienics Holdings Inc. (OTCQB: GRYN)

The QualityStocks Daily Newsletter would like to spotlight Green Hygienics Holdings Inc. (OTCQB: GRYN).

Green Hygienics Holdings Inc. (OTCQB: GRYN) was featured today in the 420 with CNW by CannabisNewsWire. After months of restricting access to its recreational cannabis industry, Michigan has loosened a key restriction that kept many from acquiring a recreational cannabis license. Beginning on March 1, 2021, applicants for five types of recreational cannabis licenses will not be required to have an active medical marijuana license to qualify. The state initially put this policy in place to allow the companies that first invested in cannabis to become established and recoup their costs before the industry was filled with sellers, says the director of the Michigan Cannabis Industry Association.

Green Hygienics Holdings Inc. (OTCQB: GRYN) is a California-based innovative technology-driven enterprise focused on the high standard cultivation and processing of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids.

The company aims to be a leader in compliance and capabilities in the hemp and cannabinoid supply marketplace. By leveraging state of the art technologies, the company intends to open up a whole new world of novel cannabinoids and targeted bio-delivery technologies never before explored, solving the issues of stability, pharmacokinetics, biological tissue penetration and bioavailability.

Dedicated to creating the hemp industry’s safest and finest quality products, the company will be uniquely positioned to deliver product efficacy and supply chain solutions to consumers, as well as to leverage these within its own products and brand portfolio.

USDA Organic Certification and FDA Registration

On August 26, 2020, Green Hygienics registered with the U.S. Food and Drug Administration pursuant to the Federal Food Drug and Cosmetic Act, as amended by the Bioterrorism Act of 2002. This registration strengthens the company’s core mission to provide product efficacy to the pharmaceutical industry and consumers alike.

On September 30, 2020, Green Hygienics was granted USDA Organic Certification (7 CFR Part 205) for the cultivation and post-harvest processing of industrial hemp by the California Certified Organic Farmers for its Sol Valley Ranch property. This certification further enables the company to supply certified organic hemp products to national and international markets.

Market Opportunity

Green Hygienics is focused on finding, acquiring and developing strategically positioned businesses, as well as the best innovations within the hemp industry – a fast-progressing market with remarkable opportunities for growth. The industrial hemp market is expected to reach $5.33 billion in 2020 and is projected to rise to $15.26 billion by 2027, achieving a CAGR of 15.8%, per Grand View Research.

Capital Structure

GRYN has less than 42 million shares outstanding, fully diluted. The company has just 7.2 million common shares in float and boasts a balance sheet with no toxic debt or overhang.

Key Management

Dr. Levan Darjania serves as the company’s Chief Science Officer. Darjania has over 26 years of experience in biotechnology and pharmaceutical drug development. His research and development experience has led him to develop many in-house and collaborative R&D programs over the course of his career.

Kyle MacKinnon serves as GRYN’s Chief Operating Officer. He has extensive knowledge in cannabis processing and was previously the Business Development Manager of Advanced Extraction Systems Inc., a leader in CO2 Supercritical Fluid Extraction. MacKinnon brings over 20 years of sales and management experience to the company.

Ronald Loudoun is the President, CEO, Secretary and Director of Green Hygienics. He received an undergraduate business degree from the British Columbia Institute of Technology. Before joining Green Hygienics, he was the founder and a director of renewable energy firm Archer CleanTech Inc.

Jerry Halamuda is the Senior Vice President of Business Development of the company’s Agriculture Division. He has an extensive career working in the agriculture and horticulture industry. Halamuda has founded, managed and operated multiple successful companies, including Color Spot Nurseries.

John Gildea is GRYN’s Senior Vice President of Corporate Development. He has over 20 years of experience working within the private and public markets. His expertise includes negotiating and structuring private and public financing and mergers. During the course of his work, Gildea has established trusted relationships with a network of equity and capital partners.

 

Green Hygienics Holdings Inc. (OTCQB: GRYN), closed Thursday's trading session at $1.04, off by 5.8824%, on 29,840 volume with 60 trades. The average volume for the last 3 months is 32,700 and the stock's 52-week low/high is $0.300000011/$1.49.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

closed Monday's trading